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Abstract
Introduction Nutraceuticals (NUT) are forms of com-
pounds with biological activity commonly used to improve
health in dosage largely exceeding those obtainable in
food.
Aim We compared, in a double blind randomized cross-
over trial, the effects of two NUT combinations on the
control of glico-lipidic metabolism in patients with hy-
percholesterolemia not on statins.
Methods At study start patients were given dietary
counseling and received placebo for 2 weeks. After this
run-in period, patients were randomized: (1) Combination
A [Policosanol, Red yeast rice (Monakolin K 3 mg), Ber-
berine 500 mg, Astaxantine, Folic Acid and Coenzyme
Q10] for 4 weeks followed by 4 weeks of Combination B
[Red yeast rice (Monakolin K 3.3 mg), Berberine
531.25 mg and leaf extract of Morus alba]; (2) Combina-
tion B for 4 weeks followed by 4 weeks of Combination A.
Results Combination B reduced LDL cholesterol below
130 mg/dl in 56.5 % of the patients, and Cambination A
only in 21.7 % of them (p B 0.027). Both treatments re-
duced plasma levels of triglycerides, total and LDL
cholesterol and increased HDL cholesterol (all p\ 0.03).
Total and LDL cholesterol reduction was more pronounced
in patients taking Combination B (p\ 0.005). Combina-
tion B reduced also glycated hemoglobin, fasting glucose
and insulin plasma levels as well as HOMA index
(p\ 0.005).
Conclusions An increased content of Berberin and
Monacolin K and the addition of Morus alba extract im-
proves the effect on plasma cholesterol and on glucose
metabolism of the NUT Combination. These effects may
allow the speculation of a more marked improvement in
cardiovascular prognosis.
Keywords Nutraceuticals  Hypercholesterolemia 
Insulin sensitivity
1 Introduction
International guidelines for treatment of dyslipidemia
suggest the use of nutraceuticals (NUT) as first line choice
for the treatment of patients with hypercholesterolemia and
at low or moderate cardiovascular risk [1], since in ran-
domized trials it has been demonstrated that some combi-
nations of NUT are able to significantly improve the lipid
profile and, consequently, the cardiovascular prognosis [2].
However, there are two issues that still deserve inves-
tigation: (1) the observation that the percentage of patients
reaching the target level of serum LDL with NUT treat-
ment is still low; (2) the knowledge that despite the marked
reduction in serum LDL concentration obtained in large
interventional trials, the percentage of patients who expe-
rience a cardiovascular event remains elevated so that it
has been defined the ‘‘forgotten majority’’ [3].
With regard to NUT cholesterol lowering treatment, it
seems reasonable to hypothesize that to overcome the
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problem of the low percentage of subjects reaching the
therapeutic target, it may be useful the use of NUT com-
binations which include more components in order to re-
cruit several different mechanisms able to improve the lipid
profile.
In order to organize a strategy to reduce the ‘‘forgotten
majority’’ it is relevant to consider that dyslipidemia is just
one of the determinants of cardiovascular prognosis, while,
according to the philosophy of the global cardiovascular
risk, a combined activity on more than one risk factor may
be required to reduce the probability to develop acute
cardiovascular events [3].
In particular, Khaw et al. [4] demonstrated in a large
population without known diabetes that the risk for car-
diovascular disease and total mortality is associated with
glycated hemoglobin (HbA1c) concentrations and in-
creases continuously through the sample distribution.
Furthermore, it has been reported that fasting glucose,
fasting insulin and insulin sensitivity, as expressed by
Homeostasis Model Assessment Insulin Resistance
(HOMA) index, were associated with incident cardiovas-
cular disease in individuals without diabetes [5].
Recently, Wang et al. [6], have reported that Morus
alba, mulberry fruit, used to treat and prevent diabetes in
traditional oriental medicine, exerts an a-glucosidase in-
hibitory and antioxidant activity in vitro, which may reduce
postprandial glucose peak, thus improving HbA1c
concentration.
We planned the present study to compare in a double
blind randomized trial the effects of two NUT combina-
tions on the control of serum LDL levels (percentage of
subjects reaching the target therapeutic level) and glucose
metabolism and endothelial function in patients with hy-
percholesterolemia not requiring statins or statin intolerant.
2 Methods
This was a monocentric, 8-week, randomized, double-
blind, cross-over, placebo-controlled study during which
all subjects assumed placebo for 2 weeks and subsequently
NUT Combination A or Combination B according to a
cross-over randomized double blind design, so that all
patients received both NUT Combinations. All determi-
nations were performed at the end of each of the three
study steps.
The primary endpoint was the percentage of patients
obtaining normalization of LDL plasma levels (LDL
\130 mg/dl). Secondary end points were the changes in
total, HDL and LDL cholesterol, triglycerides, Hb1Ac,
fasting glucose and insulin plasma levels, improvement of
insulin sensitivity index (HOMA index) and endothelial-
dependent dilation (FMD) in relation to the administration
of each NUT Combination.
The study was conducted in accordance with the
guidelines of the declaration of Helsinki, and the study
protocol was approved by the Ethic Committee of the
Federico II University of Naples. Written informed consent
was obtained from each subject.
The inclusion criteria were hypercholesterolemia not
requiring statins or in statin intolerant subjects, age be-
tween 18 and 70 years.
We excluded from the study subjects with intolerance to
NUT compounds, pregnant women and women planning to
conceive, patients treated with lipid lowering drugs during
the previous 6 weeks and patients with severe hyper-
triglyceridemia ([500 mg/dl).
2.1 Protocol
After the screening visit and recruitment, patients were
given dietary counseling, according to their clinical con-
ditions and received placebo for 2 weeks. At the end of this
run-in period, patients were randomized into two arms
assigned to receive: (1) Combination A for 4 weeks fol-
lowed by a 4 week treatment with Combination B; (2)
Combination B for 4 weeks followed by 4 week treatment
with Combination A. After all study section blood pressure
(BP), heart rate, waist girth, lipid and glucose profile,
plasma levels of insulin and HbA1c and FMD were
assessed.
2.2 Measurements and Definitions
Fasting plasma glucose, lipids, insulin and HbA1c were
measured by standard methods. Waist circumference was
measured at each visit as midway between the lowest rib
and the iliac crest using an anthropometric tape. Systolic
and diastolic BP were measured by standard sphygmo-
manometer after 5 min in the supine position, according to
the guidelines of the European Society of Hypertension/
European Society of Cardiology [7].
2.3 Nut Combinations
The Combination A contains: Policosanol (10 mg), Red
yeast rice (200 mg; 3 mg monacolin K), Berberine
(500 mg), Astaxantine (0.5 mg), Folic Acid (200 mcg) and
Coenzyme Q10 (2 mg). This combination is approved in
Italy for the control of dyslipidemia (Armolipid Plus,
RottapharmSpA).
The Combination B contains: Berberine (531.25 mg),
Red yeast rice powder (220 mg; 3.3 mg monacolin K) and
leaf extract of Morus alba (200 mg). This product has
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recently been approved in Italy (LopiGLIKTM, Akademy
Pharma).
2.4 Endothelial Function
Endothelial function was assessed with the flow-mediated
dilation test (FMD) by digital pulse amplitude, using a fin-
gertip PAT as previously described [8]. The system (Itamar
Medical Ltd., Caesarea, Israel) consists of a finger probe to
assess digital volume changes accompanying pulse waves.
All subjects included in the study were maintained without
smoking, alcohol or caffeine from the night before the
evaluation. Reactive hyperemia was measured as a PAT
reactive hyperaemic index (RHI) calculated as the ratio of
the average amplitude of the PAT signal over a 1-min time
interval starting 1-min after cuff deflation divided by the
average amplitude of the PAT signal of a 3.5-min time period
before cuff inflation (baseline) and normalized to the RHI of
the control arm. Endothelial dysfunction was defined as a
RHI B1.68 calculated by the mean value minus 2 standard
deviations of 20 healthy asymptomatic control individuals
without history of cardiovascular disease and without major
cardiovascular risk factors.
2.5 Statistical Analysis
Sample power was calculated based on a target LDL
cholesterol levels\130 mg/dL, with a power of 80 % and
an a-error = 5 % with a predicted success in subjects
taking the experimental medications of 90 %, compared to
40 % of the control group, adjusting for cross-over. Ac-
cording to this calculation, 22 patients are required to have
80 % chance of detecting a significant increase in the pri-
mary outcome measure from 40 % in the control group to
90 % in the experimental group [9].
Data were analyzed using SPSS (version 22.0; SPSS,
Chicago, Illinois, USA) and expressed as mean ± SD. All
variables deviating from normal distribution were log
transformed before parametric statistics were calculated.
Descriptive statistics were performed using ANOVA or v2-
distribution, with Monte Carlo simulation to generate exact
p values. The paired t test was used to calculate the sig-
nificance of difference from baseline in each arm and inter
group. The Sidak correction was applied for multiple
comparisons. The null hypothesis was rejected for two-
tailed a value less than 0.025.
3 Results
Twenty three patients were enrolled in the study (mean age
59.48 ± 6.3; 52 % women).
Baseline demographic and clinical characteristics of the
study population were reported in the Table 1. No patient
was taking any drug except the study treatment, in par-
ticular, although average systolic BP levels were slightly
above the normal thresholds, hypertensive patients were at
low-to-moderate global cardiovascular risk profile and
consequently, according to current ESC/ESH guidelines,
they did not require any pharmacological therapies before
life-style changes. No significant difference in weight,
waist circumference, systolic and diastolic BP were
recorded during the study (data not shown). No adverse
event was reported.
The comparison between the percentages of subjects in
whom LDL cholesterol was reduced below 130 mg/dl at
the end of each of the two active treatment periods shows a
statistically significant difference with a larger number of
individuals with a normal value of plasma LDL cholesterol
with Combination B as compared to Combination A (56.5
vs 21.7 %, v2 = 0.027) (Fig. 1).
Table 1 Baseline characteristics of the study population (each value
represents mean ± SD)
N = 23
Age (year) 59.5 ± 6.3
Gender (M/W %) 48/52
SBP (mmHg) 142.5 ± 14.1
DBP (mmHg) 85.5 ± 10.9
Waist circumference (cm) 95.4 ± 9.4
Total cholesterol (mg/dl) 246.1 ± 15.1
HDL cholesterol (mg/dl) 47.4 ± 10.8
LDL cholesterol (mg/dl) 175.7 ± 13.4
Triglycerides (mg/dl) 114.9 ± 41.6
Fasting plasma glucose (mg/dl) 92.0 ± 7.53
BMI (Kg/m2) 26.8 ± 3.6
HbA1c ( %) 5.6 ± 0.4






Fig. 1 Percentage of subjects with LDL\130 mg/dl at the end of
active treatment (N = 23; v2 = 0.027)
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Table 2 shows lipid profile at baseline and after treat-
ment with Combination A and Combination B. Both
treatments induce a significant reduction of plasma levels
of triglycerides, total and LDL cholesterol and an increase
of HDL cholesterol (all p\ 0.03). Combination B therapy
showed a further advantage in the reduction of total and
LDL cholesterol as compared to Combination A (both
p\ 0.005). For all these parameters we calculated the
percentage change obtained by both Combinations vs
baseline. Combination B decreased the values of total and
LDL cholesterol more than Combination A (p = 0.004 and
p = 0.005, respectively). No significant difference was
recorded in the percentage changes of triglycerides and
HDL cholesterol observed with the two NUT Combina-
tions (Fig. 2).
When the parameters of glucose metabolism were ex-
amined, there was a significant reduction for serum fasting
glucose, insulin and HbA1c only after treatment with the
NUT Combination B (Table 3). As a consequence, there
was also a significant difference between these values and
the corresponding ones recorded at the end of the NUT
Combination A treatment (Table 3). None of the patients
experienced a clinically evident hypoglycemia.
We calculated the HOMA index, according to the for-
mula by Matthews [10], to evaluate the effects of two NUT
Combinations on insulin resistance. Only Combination B
induced an improvement in insulin sensitivity reaching a
value which was statistically significantly different from
baseline and from NUT Combination A (p = 0.006 vs
baseline and p = 0.002 vs Combination A) (Table 3).
No statistically significant difference was detectable
among the absolute values of FMD recorded throughout the
study (RHI baseline = 2.04 ± 0.8; RHI NUT
A = 1.99 ± 0.6; RHI NUT B = 2.02 ± 0.5)
4 Discussion
This randomized, cross-over, double-blind study confirms
that 4 weeks of treatment with a NUT Combination ap-
proved in Italy for the control of dyslipidemia (Armolipid
Plus, RottapharmSpA), is able to improve the lipid profile
in patients with hypercholesterolemia not requiring statins
or statin intolerant [2, 11].
However, the addition of the extract of Morus alba,
NUT with an a-glucosidase inhibitory and antioxidant
Table 2 Lipid profile at the end of the three study periods (each value represents mean ± SD; N = 23)






Total cholesterol (mg/dl) 246.1 ± 15.1 213.6 ± 18.7 197.9 ± 28.4 0.0001 0.0001 0.008
HDL cholesterol (mg/dl) 47.4 ± 10.8 51.8 ± 13.0 52.5 ± 13 0.03 0.02 NS
LDL cholesterol (mg/dl) 175.7 ± 13.4 142.5 ± 17.1 126.8 ± 27.8 0.0001 0.0001 0.01
Triglycerides (mg/dl) 114.9 ± 41.6 96.2 ± 43.9 93.3 ± 38.4 0.0001 0.0001 NS

















Fig. 2 Percentage changes in
lipid profile (each bar represent
mean ± ST; N = 23;
*p\ 0.005)
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activity, potentiates the cholesterol lowering effect of the
NUT combination. In particular, reasonably an account of a
more complete action on plasma lipids, this NUT Combi-
nation was able to normalize serum LDL concentration in
about fifty percent of the study population. This higher
percentage of favorable therapeutic responses resulted in a
more marked reduction in the mean level of plasma total
and LDL cholesterol levels obtained with this NUT Com-
bination as compared to the other active treatment.
The decision to addMorus alba to the NUT combination
was mainly based on the observation that this NUT is able
to exert an antioxidant and a-glucosidase inhibitory ac-
tivity, which may stand for, at least in part, the high hy-
poglycemic capacity of Morus alba extract that accounts
for its diabetic prevention activity [6]. However, studies
in vitro and in vivo have also reported a favorable effect of
this NUT on lipid profile[12], thus it is not surprising that it
may be able to potentiate the reduction in total and LDL
cholesterol exerted by previous NUT Combinations.
In addition, the results of our study lend further support
to the evidence that Morus alba improves glucose meta-
bolism [6] and, consequently, to the possibility that a
combination with this NUT, may act on the global car-
diovascular risk also trough mechanisms different from a
cholesterol lowering effect. Since a continuous relationship
between HbA1c and cardiovascular disease as well as all-
cause mortality has been reported both in men and women
without diabetes, we used HbA1c to assess whether there
was an effect of the NUT Combination including Morus
alba on glucose metabolism which may improve cardio-
vascular prognosis. A reduction in HbA1c was observed,
which was statistically significant but small in magnitude.
However, it is well accepted that Hb1Ac is a reliable index
of the behavior of glycaemia in the preceding 3 months
[13, 14]. Thus, even a small reduction in Hb1Ac induced
by a 4 week treatment may indicate a clinically relevant
change in glucose metabolism. The simultaneous reduction
in fasting glucose and insulin is consistent with the re-
duction of HbA1c and may be explained by the improve-
ment of insulin sensitivity observed during treatment with
the NUT-Morus alba combination.
The lack of improvement in insulin sensitivity during
the treatment with the NUT without Morus alba is in
contrast with a previous report [11], in which this effect
was documented. However, in that study most patients
were overweight or frankly obese (mean BMI 28 ± 3.8 kg/
m2) and were studied over a longer follow-up. The absence
of data on changes in body weight did not rule out the
possibility that the improvement in insulin sensitivity could
be due to weight loss. Another difference from the Affuso’s
study is that we failed to detect improvement in FMD re-
lated to NUTS. On the contrary, in the previous report [11]
it was described a statistically significant increase in FMD
in patients treated with the NUT combination without
Morus alba. Indeed, the analysis of the individual re-
sponses of our study population clearly shows a difference
in the effect of treatment on FMD between subjects
showing normal or impaired FMD at baseline. The per-
centage change reported by Affuso is similar in magnitude
to what we observed with both treatments in subjects with
impaired FMD at baseline. Therefore, it seems possible to
speculate that in our study we failed to achieve a statisti-
cally significant change in FMD on account of a larger
heterogeneity of our population.
Although our results do not clarify the mechanisms
underlying the favorable effect of NUT Combination in-
cluding Morus alba on glucose metabolism, the observa-
tion of a reduction in fasting plasma glucose concentration
seems to rule out the possibility that it may be mediated by
the inhibition of a-glucosidase, which interferes with glu-
cose absorption, and to suggest that it may represent a
possible consequence of improved insulin sensitivity on
hepatic gluconeogenesis. Finally it has to be considered
that, though alpha-glucosidase inhibitors act mostly on
post-prandial glycaemia, chronic treatment with these
drugs has been shown to reduce also fasting blood glucose
in clinical trials [15].
4.1 Limitations
The results of this study should be interpreted in light of
several limitations.
Table 3 Glucose metabolismat the end of the three study periods (each value represents mean ± SD; N = 23)






Fasting plasma glucose (mg/dl) 92.00 ± 7.5 93.65 ± 13.7 84.35 ± 7.7 NS 0.0001 0.0001
Insulin (lU/ml) 10.1 ± 6.8 10.2 ± 6.6 7.9 ± 5.5 NS 0.006 0.02
HOMA index 2.33 ± 1.7 2.45 ± 1.7 1.66 ± 1.1 NS 0.006 0.002
HbA1c (mmol/mol) 38.00 ± 4.2 37.85 ± 4.1 37.22 ± 4.1 NS 0.002 0.03
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Despite the study results showed a significant im-
provement of lipid and glycemic profile, the limited num-
ber of patients requires confirmation in a larger population
The limited follow up time reduces the possibility to
generalize the data observed on HbA1c levels reduction,
which requires a longer period of observation to evaluate
the variations.
However, these preliminary results are very encouraging
and could be considered hypothesis generating for a larger
trial.
Finally, since available literature data demonstrate the
positive effects of berberine on glycemic control, both in
diabetic and dysglicemic patients [16, 17], it is also to
consider the possibility that the small sample study
population may account for the lack of changes on glucose
profile during treatment with NUT Combination A.
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